AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in low-quality studies
Number of subjects: 5496
Study 26208920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and ASA
Number of subjects: 0
Study 26208920 — intervention group
Group type: COMPARATOR
Intervention: Generic clopidogrel and ASA
Number of subjects: 0
Study 26208920 — intervention group
Group type: COMPARATOR
Intervention: Branded clopidogrel and ASA
Number of subjects: 0
Study 26209332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine release measured by IL-6, IL-8, CXCL1, TGF-β and CD40L at 5 different time points during liver transplantation
Number of subjects: 17
Study 26209332 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE) and Tissue Doppler Imaging (TDI) monitoring
Number of subjects: 17
Study 26209332 — intervention group
Group type: EXPERIMENTAL
Intervention: Postreperfusion syndrome
Number of subjects: 17
Study 26209332 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic parameters and variations of TEE parameters
Number of subjects: 17
Study 26210388 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of control eating (LCE)
Number of subjects: 329
Study 26210388 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively large binge episodes (OBEs)
Number of subjects: 329
Study 26210388 — intervention group
Group type: COMPARATOR
Intervention: No loss of control eating
Number of subjects: 329
Study 26210442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of busulfan over 90 hours
Number of subjects: 54
Study 26210442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of busulfan with intermittent fludarabine
Number of subjects: 54
Study 26210474 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in ICU
Number of subjects: 499
Study 26210474 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in ED
Number of subjects: 499
Study 26210474 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV on general wards
Number of subjects: 499
Study 26210474 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in other units
Number of subjects: 499
Study 26210512 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy for four weeks in addition to standard of care
Number of subjects: 0
Study 26210512 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0
Study 26210512 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7112 with high-fat/high-energy meal
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7112 with new formulation under fasting condition
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7112 with multiple-dose administrations (4 schedules)
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7112 with liquid supplementation
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose consecutive daily dosing for 5 days
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose consecutive daily dosing for 3 days
Number of subjects: 0
Study 26210682 — intervention group
Group type: COMPARATOR
Intervention: Weekly dosing schedule
Number of subjects: 0
Study 26210682 — intervention group
Group type: COMPARATOR
Intervention: Low-dose/long-duration (20-day) daily schedule
Number of subjects: 0
Study 26210682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MIC-1 and blood platelet profiles
Number of subjects: 0
Study 26211987 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) administered i.v. on day 1 of a 21-day cycle for a total of 4 cycles
Number of subjects: 37
Study 26212068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 26212068 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation and histone deacetylase inhibitors
Number of subjects: 0
Study 26212068 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA blockade strategy
Number of subjects: 0
Study 26212068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor microenvironment targeting
Number of subjects: 0
Study 26212464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis disease burden (total joint pain and disease activity)
Number of subjects: 103
Study 26212464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood disturbance (measured by Center for Epidemiological Studies Depression Scale)
Number of subjects: 103
Study 26212464 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability (measured by Health Assessment Questionnaire disability index)
Number of subjects: 103
Study 26212464 — intervention group
Group type: EXPERIMENTAL
Intervention: Role functioning (measured by Short Form 36 health survey)
Number of subjects: 103
Study 26212872 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 303
Study 26213141 — intervention group
Group type: EXPERIMENTAL
Intervention: MK2206 (AKT inhibitor) administered orally at 200 mg once weekly in 28-day cycles up to 12 cycles; final doses included 300 mg (n=33), 250 mg (n=2), 200 mg (n=16), and 135 mg (n=8).
Number of subjects: 59
Study 26213141 — intervention group
Group type: EXPERIMENTAL
Intervention: MK2206 (AKT inhibitor)
Number of subjects: 59
Study 26213309 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP level of ≤10 mg/liter and MBDA score of >44
Number of subjects: 347
Study 26213309 — intervention group
Group type: COMPARATOR
Intervention: CRP level of >10 mg/liter
Number of subjects: 347
Study 26213313 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]FDG PET
Number of subjects: 20
Study 26213313 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 PET
Number of subjects: 20
Study 26213313 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 HV within [(18)F]FDG HV
Number of subjects: 20
Study 26213360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-staging with ≥12 LNs, H&E-negative LNs, and IHC-negative LNs (pN0i-)
Number of subjects: 203
Study 26213360 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging (pN0i+)
Number of subjects: 203
Study 26213608 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SCIT) with a standardized allergen extract from Olea europaea; up-dosing doses: 300, 600, 3000, 6000, and 15000SQ+ administered weekly, followed by a maintenance dose of 15000SQ+ after 2 weeks
Number of subjects: 93
Study 26213798 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ release assay (QFT and T-SPOT.TB)
Number of subjects: 506
Study 26213798 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test
Number of subjects: 506
Study 26213798 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ release assay-based latent infection prevalence
Number of subjects: 506
Study 26214043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier domain long-range optical coherence tomography (LR-OCT)
Number of subjects: 72
Study 26214545 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 104
Study 26214545 — intervention group
Group type: EXPERIMENTAL
Intervention: shCBT + sibutramine
Number of subjects: 104
Study 26214545 — intervention group
Group type: EXPERIMENTAL
Intervention: shCBT + placebo
Number of subjects: 104
Study 26214545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 26215720 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarkers of brain ischaemia
Number of subjects: 350
Study 26215720 — intervention group
Group type: COMPARATOR
Intervention: Definite diagnosis by a panel of three experienced neurologists
Number of subjects: 350
Study 26215832 — intervention group
Group type: EXPERIMENTAL
Intervention: TV viewing (2-hour/day increase)
Number of subjects: 221426
Study 26216294 — intervention group
Group type: EXPERIMENTAL
Intervention: LOXO-101
Number of subjects: 1
Study 26216360 — intervention group
Group type: EXPERIMENTAL
Intervention: Total specific airway resistance (sRtot)
Number of subjects: 885
Study 26216360 — intervention group
Group type: COMPARATOR
Intervention: Forced expiration volume in 1 second (FEV1)
Number of subjects: 885
Study 26216360 — intervention group
Group type: COMPARATOR
Intervention: Forced expiration volume in 1 second to forced vital capacity ratio (FEV1/FVC)
Number of subjects: 885
Study 26216692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezogabine/retigabine (EZG/RTG)
Number of subjects: 203
Study 26217225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) at doses of 0.3, 1, 2, or 3 μg/kg/min infused for 30 min followed by open-label administration for at least 90 min.
Number of subjects: 203
Study 26217506 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated obesity management system (preceptorships with a virtual community and on-site coaching)
Number of subjects: 220
Study 26217506 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice guidelines (control group)
Number of subjects: 220
Study 26217506 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated obesity management system
Number of subjects: 220
Study 26217532 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-delivered peer support weight loss intervention
Number of subjects: 22
Study 26217540 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus polyglucosamine (ST + PG)
Number of subjects: 115
Study 26217540 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plus placebo (ST + PL)
Number of subjects: 115
Study 26217539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Maintenance (continued in-person visits)
Number of subjects: 79
Study 26217539 — intervention group
Group type: COMPARATOR
Intervention: Standard Maintenance (received materials by mail or e-mail)
Number of subjects: 79
Study 26217539 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (during active weight loss phase, months 0-6)
Number of subjects: 79
Study 26217542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Number of subjects: 70
Study 26217542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 70
Study 26217542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 60000 IU
Number of subjects: 70
Study 26217542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 26218032 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis
Number of subjects: 211
Study 26218032 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis
Number of subjects: 211
Study 26218032 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prophylaxis
Number of subjects: 211
Study 26218032 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 211
Study 26218032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhibitors observed)
Number of subjects: 211
Study 26218032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 211
Study 26218540 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8329 (single oral doses or repeat daily doses for 7-9 days)
Number of subjects: 0
Study 26218540 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPOUND-20 (single oral doses or repeat daily doses for 7-9 days)
Number of subjects: 0
Study 26218540 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPOUND-20 (continuous cover for 7 days)
Number of subjects: 0
Study 26218540 — intervention group
Group type: EXPERIMENTAL
Intervention: Human and rat AT
Number of subjects: 0
Study 26218540 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine disease models
Number of subjects: 0
Study 26221138 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (50 mg/d) for 12 weeks
Number of subjects: 13
Study 26221665 — intervention group
Group type: EXPERIMENTAL
Intervention: Generative probabilistic approach to discover disease subtypes determined by genetic variants.
Number of subjects: 0
Study 26221665 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated data evaluation of the generative method.
Number of subjects: 0
Study 26222441 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgam (normal immunoglobulin, IgG) given weekly as a rapid subcutaneous infusion
Number of subjects: 50
Study 26222558 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX3397 (1000 mg per day)
Number of subjects: 23
Study 26222814 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-breath forced oscillation technique in COPD patients
Number of subjects: 114
Study 26222814 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-breath respiratory impedance parameters in COPD patients
Number of subjects: 114
Study 26222814 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-to-peak impedance (Zpp) in COPD patients
Number of subjects: 114
Study 26222814 — intervention group
Group type: EXPERIMENTAL
Intervention: Various impedance measures (Zm, Zi, Ze, Zbe, Zpp, ΔZrs) in severe and very severe COPD patients
Number of subjects: 114
Study 26222814 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of respiratory impedance with spirometric indices of airway obstruction
Number of subjects: 114
Study 26222884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 42-day packed red cells
Number of subjects: 18
Study 26222884 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of 5-day blood
Number of subjects: 18
Study 26222884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of aged stored blood
Number of subjects: 18
Study 26222884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 42-day-old blood
Number of subjects: 18
Study 26223436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 9 mg/kg/week
Number of subjects: 22
Study 26223436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 15 mg/kg/week
Number of subjects: 22
Study 26223436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 35 mg/kg/3-weekly
Number of subjects: 22
Study 26223436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 25 mg/kg/3-weekly
Number of subjects: 22
Study 26223436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575
Number of subjects: 22
Study 26223768 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir and daclatasvir
Number of subjects: 12
Study 26223897 — intervention group
Group type: EXPERIMENTAL
Intervention: High AGE diet (4-fold increase)
Number of subjects: 20
Study 26223897 — intervention group
Group type: COMPARATOR
Intervention: Low AGE diet
Number of subjects: 20
Study 26223897 — intervention group
Group type: EXPERIMENTAL
Intervention: High AGE diet
Number of subjects: 20
Study 26224016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed invitation to annual skin examination by a general practitioner (GP)
Number of subjects: 3897
Study 26224101 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of parmesan cheese, a boiled egg and 300 ml of water
Number of subjects: 35
Study 26224101 — intervention group
Group type: COMPARATOR
Intervention: 500 ml of water
Number of subjects: 35
Study 26224646 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 9
Study 26224646 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 9
Study 26225497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 40
Study 26225497 — intervention group
Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 40
Study 26227009 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary superoxide scavenging activity
Number of subjects: 160
Study 26227009 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary hydroxyl radical scavenging activity
Number of subjects: 160
Study 26227009 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1β levels
Number of subjects: 160
Study 26227009 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels
Number of subjects: 160
Study 26227009 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8 levels
Number of subjects: 160
Study 26227106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab, tacrolimus/MPA with early sirolimus conversion
Number of subjects: 15
Study 26227192 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels of 7.1% to 8.0%
Number of subjects: 764
Study 26227192 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels of 8.1% to 9.0%
Number of subjects: 764
Study 26227192 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels of 9.1% to 10.0%
Number of subjects: 764
Study 26227192 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels of >10.0%
Number of subjects: 764
Study 26227192 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HbA1c variable
Number of subjects: 764
Study 26227196 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging disease-modifying treatments for aortic stenosis
Number of subjects: 0
Study 26227196 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive imaging techniques
Number of subjects: 0
Study 26227782 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCO classification
Number of subjects: 4467
Study 26228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 312
Study 26228403 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion
Number of subjects: 60
Study 26228403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26228486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% and 0.06% topical resiquimod gel
Number of subjects: 12
Study 26228970 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive chemoradiotherapy (eCRT)
Number of subjects: 34
Study 26228971 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (conformal 3D planning or intensity modulated radiotherapy) to a cumulative dose of approximately 40 Gy; systemic therapy maintained unaltered.
Number of subjects: 25
Study 26228971 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 25
Study 26229116 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and in vivo growth conditions for bacterial species
Number of subjects: 0
Study 26229116 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex bacterial communities
Number of subjects: 0
Study 26229965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistocardiography (BCG) foil
Number of subjects: 22
Study 26229965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistocardiography (BCG) foil with quality index
Number of subjects: 22
Study 26230182 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exoskeleton-assisted walking
Number of subjects: 8
Study 26230482 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in somatic depressive symptoms
Number of subjects: 457
Study 26230482 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cognitive-affective depressive symptoms
Number of subjects: 457
Study 26230660 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-16
Number of subjects: 108
Study 26230660 — intervention group
Group type: COMPARATOR
Intervention: miRNA profiling (hsa-miR-369-3p, hsa-miR-376a, hsa-miR-376, hsa-miR-411#, hsa-miR-411, mmu-miR-379)
Number of subjects: 108
Study 26230660 — intervention group
Group type: COMPARATOR
Intervention: miRNAs in plasma
Number of subjects: 108
Study 26231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma total omega-3 PUFA concentrations
Number of subjects: 698
Study 26231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma omega-6:omega-3 PUFA ratios
Number of subjects: 698
Study 26231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher arachidonic acid:docosahexaenoic acid, AA:eicosapentaenoic acid, and AA:docosapentaenoic acid ratios
Number of subjects: 698
Study 26231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PUFAs
Number of subjects: 698
Study 26231011 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma omega-3 fatty acids and omega-6:omega-3 fatty acid ratios
Number of subjects: 698
Study 26231256 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mismatch patients
Number of subjects: 23
Study 26231264 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 102
Study 26231264 — intervention group
Group type: COMPARATOR
Intervention: Serum ferritin
Number of subjects: 102
Study 26231264 — intervention group
Group type: COMPARATOR
Intervention: Periodic limb movements in sleep
Number of subjects: 102
Study 26231264 — intervention group
Group type: COMPARATOR
Intervention: Polysomnogram parameters
Number of subjects: 102
Study 26231842 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe LV end-diastolic diameter
Number of subjects: 930
Study 26231842 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe LV mass
Number of subjects: 930
Study 26231842 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-diastolic diameter
Number of subjects: 930
Study 26232340 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 12552
Study 26232910 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 4317
Study 26232910 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 4317
Study 26233552 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) in PSC patients
Number of subjects: 35
Study 26233552 — intervention group
Group type: COMPARATOR
Intervention: Probe-based confocal laser endomicroscopy (pCLE) in non-PSC patients
Number of subjects: 35
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS (Crohn's Disease Endoscopic Index of Severity)
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD (Simple Endoscopic Score for Crohn's Disease)
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD large ulcers
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS deep ulceration
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS ulcerated surface
Number of subjects: 25